Suven Life Sciences Ltd - 530239 - Submission Of Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 31St March, 2019
With reference to above subject, please find enclosed Compliance Certificate for the half-year ended 31st March, 2019 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. Suven Life Sciences Ltd - 530239 - Outcome of Board Meeting
With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 15th April, 2019, has taken on record and approved the following matter(s). 1) Approved the enhancement of investment limits in WOS in USA Suven Neurosciences, Inc. from USD 25 Million upto USD 50 Million to undertake clinical trials on the molecules in the pipeline. 2) As per the policy approved by the Board, the information on the grant of product patents to the company and periodical updates thereon will be available henceforth on our Company's website only. Since grant of product patents per se is not material information to be notified hence the Company is discontinuing forthwith the issue of News Releases to the Stock Exchanges. Suven Life Sciences Ltd - 530239 - Intimation Under Regulation 8(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 15th April, 2019, has taken on record and approved the following matter(s). ? Approved the amended the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) and Policy on determination of legitimate purpose in pursuance to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The amended code is effective from April 1, 2019 and uploaded on our company's website Suven gets US court nod to buy assets of Rising Pharmaceuticals
Suven Life Sciences on Saturday said it has received approval from a US bankruptcy court to buy assets of Rising Pharmaceuticals through its joint ve Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven receives court approval of 'Stalking Horse' Agreement to buy the assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc. Suven Life Sciences Ltd - 530239 - Closure of Trading Window
With reference to above subject, as per the clarifications issued by stock exchanges on Clause 4 of the Schedule B of SEBI PIT Regulations, 2015 as amended the "Trading Window" for dealing in the securities of the Company will be closed from 04th April 2019 and the same will remain closed till 48 hours after the announcement of Audited Financial Results for the quarter/year ending 31st March, 2019, to the public. The Board Meeting for approving the Audited Financial Results for the quarter/year ending 31st March, 2019 will be held on or before 30th May, 2019. SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri Lanka Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences secures Product Patents in Eurasia, Europe, South Korea and Sri Lanka Suven Life Sciences Ltd - 530239 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Suven Life Sciences Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Suven Life Sciences Ltd - 530239 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Results of the Postal Ballot and E-voting- Reg.,